+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P11721(SLC11A2 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

The SLC11A2 antibody targets the solute carrier family 11 member 2 (SLC11A2), also known as divalent metal transporter 1 (DMT1) or natural resistance-associated macrophage protein 2 (NRAMP2). This transmembrane protein plays a critical role in cellular iron homeostasis by mediating the transport of ferrous iron (Fe2?) across membranes. It is essential for dietary iron absorption in the duodenum, iron recycling in macrophages, and iron uptake into peripheral tissues. SLC11A2 is widely expressed, with high levels in the liver, kidneys, and brain. Dysregulation of SLC11A2 is linked to iron-related disorders, including iron-deficiency anemia, hemochromatosis, and neurodegenerative diseases like Parkinson’s.

Antibodies against SLC11A2 are valuable tools for studying its expression, localization, and function in physiological and pathological contexts. They are commonly used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to investigate tissue-specific iron transport mechanisms or mutations affecting protein stability. Polyclonal and monoclonal SLC11A2 antibodies are typically raised in rabbits or mice, with epitopes corresponding to specific regions (e.g., N-terminal, cytoplasmic loops). Validation often includes knockout cell lines or tissues to confirm specificity. Research utilizing these antibodies has advanced understanding of iron metabolism disorders and potential therapeutic targets, highlighting their importance in both basic and clinical studies.